Literature DB >> 16673333

Aeruginascin, a trimethylammonium analogue of psilocybin from the hallucinogenic mushroom Inocybe aeruginascens.

Niels Jensen1, Jochen Gartz, Hartmut Laatsch.   

Abstract

The hallucinogenic mushroom Inocybe aeruginascens contains several typical Psilocybe alkaloids including psilocybin. We have now elucidated the structure of a further indole derivative named aeruginascin as the quaternary ammonium compound N, N, N-trimethyl-4-phosphoryloxytryptamine. Aeruginascin is closely related to the frog skin toxin bufotenidine (5-HTQ), a potent 5-HT3 receptor agonist, and has been found exclusively in Inocybe aeruginascens so far.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16673333     DOI： 10.1055/s-2006-931576

Source DB:  PubMed          Journal:  Planta Med        ISSN： 0032-0943            Impact factor:   3.352


  10 in total

1.  Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov.

Authors:  Jochen Gartz; Georg Wiedemann
Journal:  Drug Test Anal       Date:  2015-03-31       Impact factor: 3.345

2.  Simultaneous Production of Psilocybin and a Cocktail of β-Carboline Monoamine Oxidase Inhibitors in "Magic" Mushrooms.

Authors:  Felix Blei; Sebastian Dörner; Janis Fricke; Florian Baldeweg; Felix Trottmann; Anna Komor; Florian Meyer; Christian Hertweck; Dirk Hoffmeister
Journal:  Chemistry       Date:  2019-12-13       Impact factor: 5.236

Review 3.  Chemistry and Toxicology of Major Bioactive Substances in Inocybe Mushrooms.

Authors:  Jiri Patocka; Ran Wu; Eugenie Nepovimova; Martin Valis; Wenda Wu; Kamil Kuca
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

4.  Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines.

Authors:  Grant C Glatfelter; Duyen N K Pham; Donna Walther; James A Golen; Andrew R Chadeayne; Michael H Baumann; David R Manke
Journal:  ACS Omega       Date:  2022-07-05

5.  Genetic Survey of Psilocybe Natural Products.

Authors:  Sebastian Dörner; Kai Rogge; Janis Fricke; Tim Schäfer; Jacob M Wurlitzer; Markus Gressler; Duyen N K Pham; David R Manke; Andrew R Chadeayne; Dirk Hoffmeister
Journal:  Chembiochem       Date:  2022-06-09       Impact factor: 3.461

Review 6.  The Therapeutic Potential of Psilocybin.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Henkel Valentine; Justin Grant; Amza Ali; Wilfred Ngwa; Lorenzo Gordon
Journal:  Molecules       Date:  2021-05-15       Impact factor: 4.411

Review 7.  Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi.

Authors:  Pawel Kosentka; Sarah L Sprague; Martin Ryberg; Jochen Gartz; Amanda L May; Shawn R Campagna; P Brandon Matheny
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

8.  Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives.

Authors:  N Milne; P Thomsen; N Mølgaard Knudsen; P Rubaszka; M Kristensen; I Borodina
Journal:  Metab Eng       Date:  2020-03-26       Impact factor: 9.783

9.  N-Salicyloyltryptamine, an N-Benzoyltryptamine Analogue, Induces Vasorelaxation through Activation of the NO/sGC Pathway and Reduction of Calcium Influx.

Authors:  Robson Cavalcante Veras; Darizy Flávia Silva; Lorena Soares Bezerra; Valéria Lopes de Assis; Walma Pereira de Vasconcelos; Maria do Carmo Alustau; José George Ferreira de Albuquerque; Fabíola Fialho Furtado; Islania Giselia de Albuquerque Araújo; Fátima de Lourdes Assunção Araújo de Azevedo; Thais Porto Ribeiro; José Maria Barbosa-Filho; Stanley Juan Chavez Gutierrez; Isac Almeida Medeiros
Journal:  Molecules       Date:  2018-01-28       Impact factor: 4.411

10.  Toxic metabolite profiling of Inocybe virosa.

Authors:  S Sai Latha; Naveen Shivanna; Mahadeva Naika; K R Anilakumar; Ankur Kaul; Gaurav Mittal
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.